In 2018, about 10,000 new cases of kidney cancer were diagnosed. This number is 30% higher than in 2012, showing that the disease has been growing.
A new drug used to treat kidney cancer has been approved by the National Health Surveillance Agency (ANVISA).
The Cabometyx is used in the treatment of kidney cancer in adults. The drug is indicated for people who have not yet received any drugs to fight the disease.
Anyone who has received drugs to fight cancer, but has not responded well to treatment can also take Cabometyx.
The laboratory that will sell the medicine here in Brazil will be Ipsen. The decision to release the drug was made after some studies that proved the drug’s efficiency.
There are several parts of the kidney that can develop cancer. In most cases, the nephrons (responsible for the formation of urine) are the structure of the organ that is affected by the disease.
The smoking , hypertension and obesity are the main kidney cancer risk factors. In addition, the treatment of hemodialysis in patients with renal failure also increases the chances of the onset of the disease.
Age can also be related to the development of the disease. Cases in people under 45 are rare. Most kidney cancer patients are over 60 years old.